ranpirnase
information and resources from the National Cancer Institute
NCI Thesaurus | ranpirnase
A natural homologue of ribonuclease A isolated from the eggs of the frog Rana pipiens. Ranpirnase primarily degrades cellular transfer RNA with a substrate specificity for uridine-guanidine base-pair sequences, resulting in inhibition of protein synthesis and cytotoxicity. This agent also activates caspase-9 in mitochondria, resulting in tumor cell apoptosis. NCI Thesaurus | ranpirnase
A natural homologue of ribonuclease A isolated from the eggs of the frog Rana pipiens. Ranpirnase primarily degrades cellular transfer RNA with a substrate specificity for uridine-guanidine base-pair sequences, resulting in inhibition of protein synthesis and cytotoxicity. This agent also activates caspase-9 in mitochondria, resulting in tumor cell apoptosis.
|
|
|
|
news articles
Alfacell Corporation to Present at Leading European Cancer ... Mar 28, 2006
PR Newswire (press release), ...in collaboration with Alfacell during her tenure at the National Cancer Institute (NCI) on a novel chemical conjugate coupling ONCONASE(R) (ranpirnase) with an ...
Alfacell Corporation to Present at Leading European Cancer ... Mar 28, 2006
Yahoo! News (press release) ...in collaboration with Alfacell during her tenure at the National Cancer Institute (NCI) on a novel chemical conjugate coupling ONCONASE® (ranpirnase) with an ...
Alfacell achieves full patient enrollment for Onconase phase IIIb ... Mar 28, 2006
Therapeutics Daily (subscription) (press release), ...target of 316 patients has been reached for the international, confirmatory phase IIIb registration trial evaluating Onconase (ranpirnase), the company's lead ...
Alfacell Corporation Reports Second Quarter 2006 Financial Results ... Mar 21, 2006
Yahoo! News (press release) ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration ...
Alfacell Achieves Full Patient Enrollment Milestone for the ... Feb 27, 2006
PR Newswire (press release), ...target of 316 patients has been reached for the international, confirmatory Phase IIIb registration trial evaluating ONCONASE(R) (ranpirnase), the Company's ...
Alfacell Corporation Announces Annual Shareholders Meeting Dec 6, 2005
PR Newswire (press release), ...expected to include the election of the Company's new Board of Directors; updates from the management team on the ONCONASE(R) (ranpirnase) confirmatory Phase ...
Alfacell Corporation Launches New Investor Relations Section of ... Nov 28, 2005
PR Newswire (press release), ONCONASE(R) (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration ...
|
|
